<DOC>
	<DOCNO>NCT01525628</DOCNO>
	<brief_summary>To evaluate drug-drug interaction BI 201335 BI 207127 well combined effect CYP probe drug substrates tenofovir raltegravir treatment naive prior treatment relapse patient chronic hepatitis C infection .</brief_summary>
	<brief_title>Drug Drug Interaction Study Between BI 201335 BI 207127 Chronic Hepatitis C Infected Patients</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<mesh_term>Protease Inhibitors</mesh_term>
	<mesh_term>Caffeine</mesh_term>
	<mesh_term>Midazolam</mesh_term>
	<mesh_term>Tolbutamide</mesh_term>
	<criteria>Inclusion criterion : 1 . Chronic hepatitis C genotype 1 infection , diagnose least 6 month prior screen 2 . Treatment naive confirm prior treatment relapse partial response follow treatment interferon ribavirin 3 . Age 18 70 year 4 . HCV RNA ( Hepatitis C Virus RiboNucleic Acid ) = 1,000 IU/mL screen 5 . Liver biopsy fibroscan exclude cirrhosis Exclusion criterion : 1 . Hepatitis C Virus ( HCV ) infection mixed genotype ; Hepatitis B Virus ( HBV ) Human Immunodeficiency Virus ( HIV ) coinfection 2 . Evidence acute chronic liver disease due cause chronic HCV infection , 3 . Decompensated liver disease , history decompensated liver disease , 4 . Body weight &lt; 40 &gt; 125 kg , 5 . Clinical evidence significant unstable cardiovascular disease , chronic pulmonary disease , history evidence retinopathy clinically significant ophthalmological disorder 6 . Preexisting psychiatric condition could interfere subject 's participation completion study 7 . Laboratory parameter disorder ( thalassemia major , sickle cell anemia glucose 6 phosphate dehydrogenase deficit ) 8 . Hemoglobin &lt; 12 g/dL woman &lt; 13 g/dL men 9 . Patients previously treat least one dose antiviral immunomodulatory drug interferon alfa ribavirin acute chronic HCV infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>